BACKGROUND: It is a fact that inflammatory scores are important prognostic factors in cancer surgery. Many data have been published last year showing that inflammation is a causative event in many cancers and a concomitant event in all malignant tumours. MONITORING OF THE INFLAMMATION: What is new is that we can assess inflammatory status during the preoperative period of our cancer patients with simple and widely available parameters, such as the neutrophil/lymphocyte ratio. This kind of biomarkers will be helpful, for the clinicians, to stratify the patients and, for the researcher, to incorporate it in clinical trials. RATIONALE FOR TRIALS AFTER DATABASE ANALYSES: Promising clinical trials, focusing on perioperative inflammation, are ongoing. Rationale for these trials came from database analyses. This kind of analyses must be extended to follow the long-term effects of our interventions. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: We have shown a correlation between non-steroidal anti-inflammatory drugs, especially ketorolac, and improved outcome (metastasis-free survival and/or overall survival) in breast and lung cancer patients. CONCLUSION: Focusing on a high-risk group with preoperative inflammation could lead to a clinical trial to test the effect of ketorolac on cancer outcome.
BACKGROUND: It is a fact that inflammatory scores are important prognostic factors in cancer surgery. Many data have been published last year showing that inflammation is a causative event in many cancers and a concomitant event in all malignant tumours. MONITORING OF THE INFLAMMATION: What is new is that we can assess inflammatory status during the preoperative period of our cancerpatients with simple and widely available parameters, such as the neutrophil/lymphocyte ratio. This kind of biomarkers will be helpful, for the clinicians, to stratify the patients and, for the researcher, to incorporate it in clinical trials. RATIONALE FOR TRIALS AFTER DATABASE ANALYSES: Promising clinical trials, focusing on perioperative inflammation, are ongoing. Rationale for these trials came from database analyses. This kind of analyses must be extended to follow the long-term effects of our interventions. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: We have shown a correlation between non-steroidal anti-inflammatory drugs, especially ketorolac, and improved outcome (metastasis-free survival and/or overall survival) in breast and lung cancerpatients. CONCLUSION: Focusing on a high-risk group with preoperative inflammation could lead to a clinical trial to test the effect of ketorolac on cancer outcome.
Authors: Antje Gottschalk; Justin G Ford; Cedric C Regelin; Jing You; Edward J Mascha; Daniel I Sessler; Marcel E Durieux; Edward C Nemergut Journal: Anesthesiology Date: 2010-07 Impact factor: 7.892
Authors: Emily J Cook; Stewart R Walsh; Naheed Farooq; Justin C Alberts; Timothy A Justin; Neil J Keeling Journal: Int J Surg Date: 2006-06-27 Impact factor: 6.071
Authors: Aristomenis K Exadaktylos; Donal J Buggy; Denis C Moriarty; Edward Mascha; Daniel I Sessler Journal: Anesthesiology Date: 2006-10 Impact factor: 7.892
Authors: Rose Christopherson; Kenneth E James; Mara Tableman; Prudence Marshall; Frank E Johnson Journal: Anesth Analg Date: 2008-07 Impact factor: 5.108
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Amanda S Peretti; Dayna Dominguez; Martha M Grimes; Helen J Hathaway; Eric R Prossnitz; Melanie R Rivera; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson Journal: Am J Pathol Date: 2017-11-21 Impact factor: 4.307
Authors: Yuna Guo; S Ray Kenney; Linda Cook; Sarah F Adams; Teresa Rutledge; Elsa Romero; Tudor I Oprea; Larry A Sklar; Edward Bedrick; Charles L Wiggins; Huining Kang; Lesley Lomo; Carolyn Y Muller; Angela Wandinger-Ness; Laurie G Hudson Journal: Clin Cancer Res Date: 2015-06-12 Impact factor: 12.531
Authors: Jae Eun Choi; John Villarreal; Javier Lasala; Vijaya Gottumukkala; Reza J Mehran; David Rice; Jun Yu; Lei Feng; Juan P Cata Journal: Cancer Med Date: 2015-03-10 Impact factor: 4.452